1. In Vivo
  2. >>Leadership

Finger On The Pulse: The State Of Biopharma Leadership

Pharma Leaders Focus On Providing A Clear Vision In The Face Of Uncertainty

 
• By Chloe Kent

In Vivo asked six biopharma figureheads to share their thoughts on the state of leadership in the life sciences space, exploring the qualities of a great leader, how recent years have shaped this role within the industry and the challenges ahead.

Graphic featuring headshots of all the interviewees
Roivant CEO Matt Gline, UPS Healthcare VP of sales Cathy O'Brien, Pfizer SVP of commercial strategy & innovation Andy Schmeltz, Celltrion USA CEO Tom Nusbickel, Ipsen chief business officer Phillipe Lopes-Fernandes, Sandoz CEO Richard Saynor • Source: Shutterstock

Recent years have seen the role of a biopharma industry leader alter drastically, with events like the COVID-19 pandemic and the war in Ukraine reshaping the day-to-day operations of the sector, from drug distribution to the dominance of remote working. In Vivo caught up with six leaders across the space – from big pharma to generics and biosimilars developers – to get their take on the changing role of a biopharma industry leader.

Matt Gline, CEO of growing biotech company Roivant Sciences Ltd., said: “That’s a hard question and I still spend...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By Ashley Yeo

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By Jo Shorthouse

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy